Fe3O4-Au Core-Shell Nanoparticles as a Multimodal Platform for In Vivo Imaging and Focused Photothermal Therapy
Metadatos
Afficher la notice complèteEditorial
MDPI
Materia
Imaging-guided therapy Multimodal imaging Contrast agent MRI CT
Date
2021Referencia bibliográfica
Caro, C.; Gámez, F.; Quaresma, P.; Páez-Muñoz, J.M.; Domínguez, A.; Pearson, J.R.; Pernía Leal, M.; Beltrán, A.M.; FernandezAfonso, Y.; De la Fuente, J.M.; et al. Fe3O4-Au Core-Shell Nanoparticles as a Multimodal Platform for In Vivo Imaging and Focused Photothermal Therapy. Pharmaceutics 2021, 13, 416. https://doi.org/10.3390/ pharmaceutics13030416
Patrocinador
Spanish Ministry of Economy, Industry and Competitiveness (CTQ2017-86655-R and BIO2017-84246-C2-1-R); Fondo Social de la DGA (grupos DGA) and by the Regional Ministry of Health of Andalusia (OH-0026-2018).; Associate Laboratory for Green Chemistry—LAQV; Applied Molecular Biosciences Unit –UCIBIO; Portuguese national funds from FCT/MCTES (UIDB/04378/2020 and UIDB/50006/2020)Résumé
In this study, we report the synthesis of gold-coated iron oxide nanoparticles capped
with polyvinylpyrrolidone (Fe@Au NPs). The as-synthesized nanoparticles (NPs) exhibited good
stability in aqueous media and excellent features as contrast agents (CA) for both magnetic resonance
imaging (MRI) and X-ray computed tomography (CT). Additionally, due to the presence of the
local surface plasmon resonances of gold, the NPs showed exploitable “light-to-heat” conversion
ability in the near-infrared (NIR) region, a key attribute for effective photothermal therapies (PTT).
In vitro experiments revealed biocompatibility as well as excellent efficiency in killing glioblastoma
cells via PTT. The in vivo nontoxicity of the NPs was demonstrated using zebrafish embryos as
an intermediate step between cells and rodent models. To warrant that an effective therapeutic
dose was achieved inside the tumor, both intratumoral and intravenous routes were screened in
rodent models by MRI and CT. The pharmacokinetics and biodistribution confirmed the multimodal
imaging CA capabilities of the Fe@AuNPs and revealed constraints of the intravenous route for
tumor targeting, dictating intratumoral administration for therapeutic applications. Finally, Fe@Au
NPs were successfully used for an in vivo proof of concept of imaging-guided focused PTT against
glioblastoma multiforme in a mouse model.